Eudald Felip
Overview
Explore the profile of Eudald Felip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Teruel I, Castella E, Recalde S, Vinas G, Petit A, Trigueros M, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596307
Triple-negative breast cancer (TNBC) is a highly aggressive subtype with limited therapeutic options, leading to higher relapse rates and mortality. Identifying prognostic biomarkers like caveolin-1 (CAV1) is crucial for personalized...
2.
Pous A, Bernat-Peguera A, Lopez-Paradis A, Cirauqui B, Quiroga V, Teruel I, et al.
Ther Adv Med Oncol
. 2024 Oct;
16:17588359241290720.
PMID: 39449733
Background: Human epidermal growth factor receptor 2 (HER2)-low has emerged as a potential new entity in breast cancer (BC). Data on this subset are limited, and prognostic results are controversial,...
3.
Pla H, Felip E, Obadia V, Pernas S, Vinas G, Margeli M, et al.
Clin Transl Oncol
. 2024 Mar;
26(7):1748-1758.
PMID: 38519708
Introduction: Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR +) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is...
4.
Gutierrez-Chamorro L, Felip E, Castella E, Quiroga V, Ezeonwumelu I, Angelats L, et al.
Cell Oncol (Dordr)
. 2023 Sep;
47(1):189-208.
PMID: 37667113
Purpose: The lack of validated surrogate biomarkers is still an unmet clinical need in the management of early breast cancer cases that do not achieve complete pathological response after neoadjuvant...
5.
Pons L, Hernandez L, Urbizu A, Osorio P, Rodriguez-Martinez P, Castella E, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370679
Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half of the patients treated with NAT...
6.
Marruecos-Querol J, Rubio-Casadevall J, Lozano A, Buxo M, Puigdemont M, Linares I, et al.
Clin Transl Oncol
. 2023 Mar;
25(8):2384-2392.
PMID: 36943650
Objective: Larynx preservation is the current standard for locally advanced (LA) laryngeal/hypopharyngeal tumors, but not all patients respond as expected. TALK score model measures four variables (T-staging, albumin levels, liquor...
7.
Prat A, Braso-Maristany F, Martinez-Saez O, Sanfeliu E, Xia Y, Bellet M, et al.
Nat Commun
. 2023 Mar;
14(1):1157.
PMID: 36859416
Liquid biopsy has proven valuable in identifying individual genetic alterations; however, the ability of plasma ctDNA to capture complex tumor phenotypes with clinical value is unknown. To address this question,...
8.
Gutierrez-Chamorro L, Felip E, Bernat-Peguera A, Ezeonwumelu I, Teruel I, Martinez-Cardus A, et al.
Front Immunol
. 2023 Feb;
14:1112761.
PMID: 36845138
Purpose: SAMHD1 is a deoxynucleotide triphosphate (dNTP) triphosphohydrolase which has been proposed as a putative prognostic factor in haematological cancers and certain solid tumours, although with controversial data. Here, we...
9.
Hernandez A, Boigues M, Felip E, Cucurull M, Notario L, Pous A, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612134
Lung cancer patients represent a subgroup of special vulnerability in whom the SARS-CoV-2 infection could attain higher rates of morbidity and mortality. Therefore, those patients were recommended to receive SARS-CoV-2...
10.
Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection
Ezeonwumelu I, Garcia-Vidal E, Riveira-Munoz E, Felip E, Gutierrez-Chamorro L, Calba I, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499329
HIV latent infection may be associated with disrupted viral RNA sensing, interferon (IFN) signaling, and/or IFN stimulating genes (ISG) activation. Here, we evaluated the use of compounds selectively targeting at...